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Abstract Since the discovery of microRNAs, non-coding
RNAs (NC-RNAs) have increasingly attracted the attention
of cancer investigators. Two classes of NC-RNAs are emerg-
ing as putative metastasis-related genes: long non-coding
RNAs (lncRNAs) and small nucleolar RNAs (snoRNAs).
LncRNAs orchestrate metastatic progression through several
mechanisms, including the interaction with epigenetic effec-
tors, splicing control and generation of microRNA-like mol-
ecules. In contrast, snoRNAs have been long considered
“housekeeping” genes with no relevant function in cancer.
However, recent evidence challenges this assumption, indicat-
ing that some snoRNAs are deregulated in cancer cells and
may play a specific role in metastasis. Interestingly, snoRNAs
and lncRNAs share several mechanisms of action, and might
synergize with protein-coding genes to generate a specific
cellular phenotype. This evidence suggests that the current
paradigm of metastatic progression is incomplete. We propose
that NC-RNAs are organized in complex interactive networks
which orchestrate cellular phenotypic plasticity. Since plastic-
ity is critical for cancer cell metastasis, we suggest that a
molecular interactome composed by both NC-RNAs and pro-
teins orchestrates cancer metastasis. Interestingly, expression
of lncRNAs and snoRNAs can be detected in biological
fluids, making them potentially useful biomarkers. NC-RNA
expression profiles in human neoplasms have been associated
with patients’ prognosis. SnoRNA and lncRNA silencing in
pre-clinical models leads to cancer cell death and/or metastasis
prevention, suggesting they can be investigated as novel ther-
apeutic targets. Based on the literature to date, we critically
discuss how the NC-RNA interactome can be explored and
manipulated to generate more effective diagnostic, prognostic,
and therapeutic strategies for metastatic neoplasms.
Keywords Longnon-codingRNAs . Small nucleolar RNAs .
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1 Introduction
For many years, the so-called central dogma of molecular
biology has been dominant in cancer research, as well as in
all other bio-medical fields [1]. This dogma assumes that the
information flow in a cell is uniquely directed from DNA to
RNA to protein, and that proteins are ultimately responsible
for cell phenotype. This paradigm has been challenged by
several new discoveries, with perhaps the most important
being the observation that while 90 % of the genome is
transcribed, just 2 % of the RNA is translated into proteins
[2, 3]. Non-coding RNAs include the well-characterized
ribosomal-RNAs (rRNAs) and transfer-RNAs, as well as
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micro-RNAs, which have been demonstrated as useful bio-
markers and therapeutic targets in several neoplasms [4–6].
Additionally, long non-coding RNAs (lncRNAs) and small
nucleolar RNAs (snoRNAs), two less investigated classes of
non-coding RNAs, are emerging as unexpected determinants
of cancer initiation, progression, and metastasis.
LncRNAs are arbitrarily defined as RNA sequences
longer than 200 bp with no protein-coding function [7].
This wide definition includes pseudogenes, micro-RNA
precursors as well as RNAs interacting with epigenetic
effectors and splicing factors. This multi-faceted group
of genes is transcribed from as many as 10,000 different
genetic loci in the human genome [8] and is involved
in the regulation of many physiological and pathological
processes [9]. Although only a small percentage of
human lncRNAs have been characterized so far, notably
most of them display either oncogenic or tumor-
suppressive functions [10].
SnoRNAs are another abundant class of non-coding
RNAs, encoded by approximately 500 different loci in the
human genome. These sequences are 60–300 base pairs long
and have been classically associated with “housekeeping”
functions, like rRNA modification and splicing [11, 12].
Due to their supposedly stable expression, some snoRNAs
have even been used as reference genes in cancer studies on
microRNAs [13]. However, emerging evidence indicates that
snoRNAs can play several non-classical roles, including reac-
tive oxygen species scavenging in the cytoplasm and being
precursors for microRNA-like molecules [14–16]. It is likely
that the whole spectrum of snoRNA functions has not yet been
fully elucidated. In parallel with those novel molecular mech-
anisms, it has become apparent that snoRNAs might play a
role in cancer progression [17].
Metastatic spreading is the main cause of cancer-related
deaths [18]. It is well known that this process requires that
cancer cells display an abnormal phenotypic plasticity,
allowing them to undergo a defined number of phenotypic
alterations (e.g., epithelial-to-mesenchymal transition, tissue
invasion, anchorage-independent growth, and homing to dis-
tant tissues) [19]. Despite a deep characterization of the
protein-related pathways involved in each step [20],
we are not currently able to account for all the molec-
ular mechanisms orchestrating this complex phenome-
non. In this paper, we summarize the emerging evidence
showing that lncRNAs and snoRNAs could play crucial
roles in several steps of the metastatic progression. We
also propose a model suggesting how non-coding RNAs
and epigenetic effectors can synergize to shape cancer
cell plasticity and drive the colonization of distant or-
gans. Finally, we indicate how fundamental research on
uncharted genomic regions could reshape the classical
landscape of translational research and eventually im-
prove the clinical outcome of cancer patients.
2 Long non-coding RNAs
Recent transcriptomic analyses of human neoplasms have
challenged the common belief that random sequential genetic
mutations occurring in protein-coding genes underlie the ac-
quisition of metastatic phenotype [21, 22]. Cancer metastasis
is a multi-step process that requires dynamic transcriptional
and translational regulation over time in response to distinct
selective pressures conferred by an evolving extracellular
environment [23–25]. Consequently, such a complex series
of events imply that additional factors must synergize with
genetic alterations to induce cancer spread [26, 27]. In line
with this idea, an increasing number of studies report that
lncRNAs represent some of the most differentially expressed
transcripts between primary and metastatic cancers [28, 29].
While some investigators have proposed that lncRNAsmainly
represent the product of leaky transcription [2], there is now
considerable evidence indicating that deregulation of these
molecules functionally drives physiological and pathological
processes. As genetic mapping and functional characterization
of lncRNAs proceeds, electronic databases have been created
to catalogue this mounting information [30] and link it to
human diseases [31].
The emergence of lncRNAs in cancer biology is already
revolutionizing our approach to translational oncology. The
past decade has revealed several examples of differentially
expressed lncRNAs carrying diagnostic and/or prognostic val-
ue, some of which are now routinely used in the clinic [32].
Interestingly, many lncRNAs are consistently associated with
clinical parameters indicative of metastasis in a wide spectrum
of tumor types [33, 34]. A notorious example of such an
oncogenic lncRNA is metastasis-associated lung adenocarci-
noma transcript 1 (MALAT1) which, as indicated by its name,
was initially found over-expressed in lung cancer metastases
[35]. Studies in different neoplasms have linked higher
MALAT1 expression with shorter metastasis-free survival
(MFS) [35], deeper tissue invasion [36], higher histological
grade [37], and shorter overall survival (OS) [38]. Analogous
to MALAT1, Homeobox transcript antisense RNA (HOTAIR)
represents another lncRNA strongly associated with metastatic
progression. Over-expression of HOTAIR occurs in about
30 % of breast neoplasms and significantly predicts shorter
MFS and OS independently of tumor size, stage, and hormone
receptor status [39]. Studies in other cancer types also identi-
fied positive correlations between HOTAIR expression and
lymph node metastasis [40], lymph-vascular invasion [41], as
well as shorter recurrence-free survival [42]. While
representing only a few examples of an increasing body of
literature, MALAT1 and HOTAIR provide a solid rationale for
developing more lncRNA-based tests aimed at assessing the
pro-metastatic potential of primary tumors.
While previously discussed lncRNAs promote metastatic
spreading, there are also many examples of oncosuppressive
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lncRNAs whose down-regulation strikingly associates with
metastatic behavior in the clinical setting. Among them,
BM742401 exhibits decreased expression in more aggressive
cancers, correlating with metastatic properties and decreased
survival in gastric cancer tissues [43]. Moreover, ectopic
expression of BM742401 significantly decreases cellular in-
vasion and migration in part by modulating the activity of
matrix metalloproteinases. Another interesting finding is that
the large majority of cancer-related single-nucleotide poly-
morphisms (SNPs) are found in non-coding regions. In fact,
only 3.3 % of cancer-related SNPs ultimately lead to a change
in amino acid at the protein level, while more than 80 % of
SNPs map to expressed non-coding regions [44]. Some of
these SNPs have been directly linked to cancer metastasis.
One such example is a SNP found in the CCAT2 lncRNA
(rs6983267), mapping to 8q24 [45, 46]. In inflammatory
breast cancer, this SNP is associated with the occurrence of
metastasis and independently predicts outcome [47]. Another
study showed that CCAT2 increases cell invasion and motility
in vitro and in vivo , correlating with shorter MFS in colon and
breast cancer [46]. Even if the majority of data on lncRNA in
cancer are just correlative, their abundance suggests that these
molecules play much more than a passive role in cancer
metastasis. In the following sections, we will review known
mechanisms of lncRNA-dependent cancer progression, which
can be primarily divided into nuclear and extra-nuclear
actions.
2.1 Nuclear mechanisms of lncRNA-induced cancer
progression
The heavily altered lncRNA transcriptome in human cancer
metastases has opened the way for a number of functional
studies to uncover the molecular mechanisms by which
lncRNAs influence cancer progression (summarized in
Fig. 1). It is now well accepted that lncRNAs are versatile
macromolecules with the potential to play multiple roles at
different stages of the metastatic process [48, 49]. While
lncRNAs vary extensively in structure and activity, their dom-
inating function occurs by physically interacting with epige-
netic complexes and recruiting them to specific loci either in
cis or in trans [50]. By doing so, lncRNAs can dynamically
orchestrate large-scale transcriptional programs required to
spatially and temporally guide the cell throughout the different
stages of the metastatic process [39, 51]. An emerging theme
for these lncRNA lies in their ability to cooperate with
polycomb repressive complexes (PRC1 and PRC2), which
have been notoriously associated with metastatic progression
and phenotypic plasticity (Fig. 1, mechanism 1) [52–55]. In
fact, it is estimated that about 20 % of all intergenic lncRNAs
have the ability to bind PRC2 [56], and a very large number of
them also regulate the activity of PRC1 [57–59]. These find-
ings indicate that lncRNAs likely play an important functional
role in epigenetic regulation of metastasis, notably through
interactions with PcG proteins.
Adding to the complex interplay between epigenetics and
lncRNAs, some genes encoding lncRNAs may also undergo
genomic imprinting [60]. The first lncRNA ever described,
H19, is the classical example of such gene [61, 62]. H19 is a
paternally imprinted lncRNA antisense to the insulin-like
growth factor 2 (IGF2) locus which exhibits loss of imprinting
and very strong up-regulation in a wide range of metastatic
neoplasms [63–65]. Supporting a driving role for H19 in
metastasis, both silencing and over-expression of H19 was
shown to modulate metastatic behavior in bladder cancer [51].
A multi-cancer study also found that H19 expression was
significantly higher in liver metastases compared to the pri-
mary tumors from which they originated [66]. The H19 pro-
moter is known to be negatively regulated by p53 [67] and
positively regulated by c-Myc [68], E2F [69], and HIF1-α
[67], providing a partial explanation for its high expression in
human metastases. To illustrate the extent of H19 over-
expression in aggressive tumors, gene therapy strategies
aimed to drive diphtheria toxin A expression under the control
of the H19 promoter are currently being tested clinically for
bladder, ovarian, and pancreatic, and colorectal cancer metas-
tases [70–73].
Studies aimed to uncover the mechanistic basis by which
H19 promotes metastatic progression have interestingly
shown that H19 can play multiple molecular functions [74],
some of which are dependent on the particular splicing variant
[75]. In bladder cancer, H19 directly binds EZH2 and recruits
PRC2 to the E-cadherin promoter, thereby suppressing E-
cadherin expression and promoting epithelial-to-
mesenchymal transition (EMT) [76]. In addition, H19 can
also regulate gene expression post-transcriptionally by serving
as a precursor for the miRNA-675, which directly targets the
tumor suppressor Retinoblastoma (Rb) [77, 78]. In colon
cancer cells, up-regulation of miRNA-675 decreases Rb
levels, which subsequently increases colony-formation ability
in soft agar, a phenotype associated with acquisition of
anchorage-independent growth [78]. Based on this property,
we propose that this miRNA-associated feature of H19 may
therefore enhance the survival of circulating tumor cells. All
these data highlight the diverse functional nature of H19
resulting in its potential to actively regulate multiple stages
of metastasis.
Recently, another chromatin-associated lncRNA,
HOTAIR, has attracted investigators’ attention due to its pro-
found pro-metastatic properties. HOTAIR has served as a
paradigm for epigenetic regulation by lncRNAs through its
ability to serve as a molecular scaffold for two histone-
modifying complexes that promote heterochromatin forma-
tion in trans [39]. Mechanistically, HOTAIR can simulta-
neously interact with both PRC2 and LSD1/CO-REST, which
catalyze histone H3K27 trimethylation and H3K4
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demethylation, respectively. When over-expressed, HOTAIR
targets these repressive complexes to anti-metastatic loci and
induces an epigenetic reprogramming enhancing cellular plas-
ticity [39, 41]. Moreover, there are reports suggesting
HOTAIR might also control DNA methylation, as its deple-
tion in Hep-2 cells lead to a decrease in phosphatase and tensin
homolog (PTEN) promoter methylation [79]. These findings
highlight HOTAIR’s versatility and support the idea that
lncRNAs can act as molecular scaffolds to bridge multiple
epigenetic complexes and therefore regulate large-scale chro-
matin dynamics.
While the previously discussed lncRNAs acted mostly in
trans , there are also a number of these transcripts that regulate
chromatin dynamics in cis (Fig. 1, mechanism 1) [80].
Antisense non-coding RNA in the INK4 locus (ANRIL) is
one characterized lncRNA working in this fashion [81].
ANRIL negatively regulates expression of the CDKN2A lo-
cus, which encodes three proteins known to inhibit tumor
progression: p14ARF, p15INK4B, and p16INK4A [59]. This
mechanism first involves a direct binding between ANRIL
and SUZ12, which recruits PRC2 and activates its catalytic
activity at the CDKN2A locus [82]. Following H3K27
trimethylation by PRC2, ANRIL then serves as a tether to
recruit the PRC1 subunit chromobox homolog 7 (CBX7),
which further represses transcription [57]. CBX7 is well
known for regulating cellular lifespan through bypassing rep-
licative senescence and providing unlimited self-renewal abil-
ity, and does so through the repression of the CDKN2A locus
[83–85]. Since metastatic cells that have reached a new organ
must repopulate a whole tumor, it is implied that they must
have acquired unlimited replicative ability despite receiving
senescence signals [86, 87]. Increased ANRIL expression
Fig. 1 Reported mechanisms by which lncRNAs can promote cancer
metastasis. 1 to 7 illustrate various mechanisms by which long non-
coding RNAs (lncRNAs) may contribute to attainment of the metastatic
phenotype in cancer cells. Mechanisms 1 and 2 are nuclear, while
mechanisms 3–7 are extra-nuclear. The name of one or two lncRNAs
functioning through the specified mechanism is shown in brackets (e.g.,
ZEB2-AS1 controls alternative splicing)
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coupled with PcG activity at the CDKN2A locus therefore
represents one way by which cells can achieve unlimited self-
renewal ability and therefore improve the efficacy of metasta-
tic tumor growth.
While most nuclear lncRNAs control multiple cellular
processes through epigenetic mechanisms, a number of them
also exert their function post-transcriptionally by regulating
alternative splicing (Fig. 1, mechanism 2) [88]. Recent studies
have demonstrated that the Zeb2 antisense RNA 1 (ZEB2-
AS1) promotes tumor invasion by directly linking the pro-
cesses of alternative splicing and metastasis, more specifically
by inducing EMT [89]. ZEB2-AS1 overlaps with an intron in
the 5′ end of the ZEB2 gene which contains an internal
ribosomal entry site (IRES) required for its translation [90].
However, this 5′ intron can be spliced, which abrogates the
translation of Zeb2 mRNA into protein. Upon transcriptional
induction by Snail, ZEB2-AS1 is expressed and prevents the
splicing of the Zeb2 5′-untranslated region. This allows reten-
tion of the ZEB2 I.E. and therefore allows synthesis of Zeb2
protein [89]. Since Zeb2 can directly inhibit E-cadherin ex-
pression and activate the EMT program, ZEB2-AS1 expres-
sion favors tumor invasion [91, 92]. This splicing mechanism
is consistent with the finding that Zeb2 protein levels increase
in cells undergoing EMT while Zeb2 mRNA levels remain
unchanged [89]. In addition to ZEB2-AS1, MALAT1 is an-
other nuclear-retained lncRNAwhich has been directly linked
to cancer metastasis and interestingly also plays a role in
alternative splicing. Also called nuclear-enriched abundant
transcript 2, MALAT1 localizes to nuclear speckles where it
regulates the phosphorylation of the pre-mRNA splicing fac-
tors such as SR proteins, thereby controlling their localization
and activity [93, 94]. However, while MALAT1 has been
directly linked to splicing control in some cellular contexts
[95], the molecular mechanisms by which this lncRNA pro-
motes metastasis need to be fully dissected [96]. Nonetheless,
by regulating SR protein activity, MALAT1 has the potential
to actively promote tumor dissemination by modifying the
splicing patterns of metastasis-related transcripts.
Besides a putative role in alternative splicing, MALAT1
may also contribute to cancer metastasis through other mech-
anisms. In fact, many studies have reported that MALAT1
plays an active role in controlling gene transcription. In lung
adenocarcinoma, MALAT1 directly regulates the expression
of pro-migratory genes such as CTHRC1, CCT4, HMMR,
and ROD1 [97]. MALAT1 can also enhance the metastatic
potential of bladder cancer by modulating the expression of
genes involved in EMT [98]. Another interesting study re-
vealed that MALAT1 can interact with the protein CBX4, a
member of the pro-metastatic complex PRC1 [99], and regu-
lates its subnuclear shuttling between polycomb bodies and
interchromatin granules [58]. Additionally, MALAT1 may
also contribute to metastasis by generating a short tRNA-like
molecule (called mascRNA) upon ribonuclease P activity
[100]. While this phenomenon has been well-described, the
function of the resulting mascRNA remains unclear. Future
studies may reveal similar post-transcriptional processing
mechanisms altering localization and function of specific
non-coding RNAs, adding another layer of complexity to the
metastasis-driving lncRNA transcriptome.
2.2 Extra-nuclear mechanisms of lncRNA-induced cancer
progression
One of the most interesting discoveries in recent years has
been that not only can lncRNAs be actively shuttled in the
cytoplasm, they can also carry out multiple pro-metastatic
functions in this subcellular compartment (Fig. 1, mechanisms
3–7) [101, 102]. For example, a subclass of lncRNAs called
pseudogenes or competing endogenous RNAs (ceRNAs) can
alter gene expression post-transcriptionally by acting as
miRNA buffers (Fig. 1, mechanism 3). Pseudogenes are
thought to arise from the duplication of protein-coding genes
followed by genomic alterations that abolish their ability to be
translated [103]. Hence, pseudogenes may retain functional
miRNA-binding sites [104], thereby buffering the pool of
miRNAs targeting their protein-coding counterpart [105].
This phenomenon confers capital importance to pseudogenes
related to metastasis-driving genes. One of the ceRNA most
relevant to cancer spreading is PTENP1, a tumor suppressive
pseudogene related to PTEN phosphatase [106]. Genomic
loss and down-regulation of PTENP1 is often found in ag-
gressive human cancers, an event correlating with PTEN
down-regulation through a miRNA-dependent mechanism
[107, 108]. Loss of PTEN function leads to PI3K phosphor-
ylation and activation of the Akt pathway, which subsequently
drives cancer cell invasion and migration [109–111].
Interestingly, a PTENP1 antisense (PTENP1-AS) transcript
was subsequently identified. PTENP1-AS inhibits PTENP1
expression through cis (RNA-RNA binding) and trans
(PRC2-dependent silencing) mechanisms, thereby playing
an oncogenic role. This multi-layer regulatory network occur-
ring in one locus suggests that ceRNAs may control multiple
targets in cancer cells, thereby acting either as pro- or anti-
metastatic genes in a context-specific manner [46]. As previ-
ously discussed for H19,many lncRNAs can themselves serve
as precursors for miRNAs, some of which are known to play
important roles in cancer progression (Fig. 1, mechanism 4)
[77]. Another example is linc00461 which is a precursor for
miRNA-9 that has the potential to target cAMP response
element-binding protein (CREB) [112]. It has been shown
that miRNA-9 over-expression inhibits proliferation but pro-
motes migration of glioma cells through CREB repression.
Interestingly, CREB and miRNA-9 are involved in an auto-
regulatory feedback loop since CREB itself can inhibit
miRNA-9 expression, suggesting interplay between different
types of non-coding RNAs may regulate cancer metastasis
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[112, 113]. With so many lncRNAs being transcribed in the
human genome [8], it is likely that many other metastasis-
related miRNAs derived from lncRNAs will be discovered.
Beside miRNA regulation, extranuclear lncRNAsmay also
promote cancer progression through specific interactions with
cytoplasmic proteins. The nature and outcome of these inter-
actions can be highly diverse, thereby allowing multiple mo-
lecular processes to be regulated by lncRNAs. For example,
one recent study has shown that the lncRNA low expression in
tumor (lncRNA-LET) can inhibit metastasis by physically
associating with NF90 and promoting its proteasomal degra-
dation (Fig. 1, mechanism 5) [114]. NF90 is an oncogenic
RNA-binding protein known to stabilize HIF1-α transcripts,
thereby promoting hypoxia-mediatedmetastasis [115, 116]. In
hepatocellular carcinomas, colorectal cancers, and squamous
cell lung carcinomas, lncRNA-LET is significantly down-
regulated which leads to NF90 up-regulation, HIF1-α
mRNA stabilization, and subsequent increase in tumor cell
invasiveness under hypoxic conditions [114]. While an influ-
ence on proteasomal degradation has only been proposed
recently, we believe a thorough analysis of the dynamic
lncRNA-protein interactome may reveal similar molecular
mechanisms promoting cellular plasticity.
Another recently discovered mechanism bywhich lncRNA
can promote metastasis is by binding specific cytoskeletal
proteins (Fig. 1, mechanism 6) and directly altering their 3D
structure and function [117]. Through this action, it is thought
that cancer cells can dynamically regulate their motility in
response to changes in lncRNA expression. Such a mecha-
nism occurs in hepatocellular carcinoma (HCC) cells express-
ing the hepatitis B virus X protein. These cells express a
lncRNA called Dreh which localizes to the cytoplasm and
physically interacts with the intermediate filament (IF) protein
vimentin, a marker of mesenchymal differentiation and EMT
[118]. Binding of Dreh alters vimentin’s structure and conse-
quently inhibits its EMT-promoting function [117]. Consistent
with this mechanism, Dreh over-expression was shown to
significantly inhibit the metastasis of HCC cells [117]. Since
the cytoskeleton plays such a crucial role in controlling cell
motility [119], altering its function through lncRNA binding
may emerge as a frequent molecular event underlying cancer
metastasis.
Finally, there is evidence supporting the idea that lncRNAs
may dynamically control the composition of the tumor micro-
environment by altering the secretion of metastasis-regulating
proteins (Fig. 1, mechanism 7). A recent study demonstrated
that the lncRNA associated with microvascular invasion in
hepatocellular carcinoma (lncRNA-MVIH) directly inhibits
secretion of phosphoglycerate kinase 1 (PGK1) [120]. Since
PGK1 promotes metastasis in some cancer types [121],
blocking its extracellular release could enhance cancer dis-
semination. This process has also been closely linked with an
increase in pro-angiogenic potential of the tumor stroma,
highlighting the tight relationship between angiogenesis and
metastasis [122]. While the exact mechanism through which
lncRNA-MVIH inhibits PGK1 secretion remains elusive, a
dynamic influence of lncRNAs on the extracellular milieu is
consistent with the idea that they represent master regulators
of cancer metastasis. These results highlight once again the
diverse nature of lncRNA interactions and strengthen the
rationale for the use of more lncRNA-based tools in transla-
tional oncology.
In summary, the considerable number of differentially
expressed lncRNAs in metastatic tumors, coupled with the
diversity of their molecular functions, challenges the assump-
tion that phenotypic plasticity is conferred solely by alter-
ations in protein-coding genes. The number of publications
linking lncRNA and metastasis has been increasing exponen-
tially in the past decade, and there is good reason to believe
that this trend will continue in the years to come.
3 Small nucleolar RNAs
SnoRNAs are an evolutionary conserved class of RNAs
expressed by all eukaryotic cells [123]. They were first dis-
covered and named after their localization in the nucleolus,
where they contribute to ribosomal RNA (rRNA) biogenesis
[124]. The synthesis of rRNA in the nucleolus requires an
intricate sequence of post-transcriptional modifications [125].
SnoRNAs are recruited into multi-protein complexes to form
ribonucleoproteins (RNP). Each snoRNA anneals with a com-
plementary rRNA sequence, thereby guiding the catalytic
activity of the nucleolar RNP (nRNP) to a specific site
(Fig. 2). Two main snoRNA (and RNP) categories are known:
C/D box, which catalyze 2′-O-methylation; H/ACA-box,
which catalyze pseudouridylation [123, 125]. Both modifica-
tions are required for accurate rRNA-mediated protein bio-
genesis [125]. SnoRNAs display considerable genetic redun-
dancy as the human genome contains at least 500 distinct loci ,
while encoding for approximately 200 functional snoRNAs
[126]. Indeed, multiple copies of the same snoRNA are
encoded by different loci , almost all of which are located in
introns of protein-coding genes. Notably, bioinformatic anal-
ysis revealed the presence of an even larger number of sup-
posedly non-functional snoRNA loci (e.g., pseudogenes) in
the human genome, raising the number of snoRNA-like genes
to over 1,000 [127]. Since snoRNA functions are not
completely elucidated, it is intriguing to speculate that
snoRNApseudogenes can play functional roles inmammalian
cells, not unlike the pseudogene fraction of lncRNAs.
As research on snoRNAs progressed, it became apparent
that these non-coding RNAs can have several non-classical
functions. Recent evidence indicates that snoRNAs can be
processed to obtain shorter sequences that are involved in
the control of mRNA alternative splicing [128]. For example,
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SNORD115, which is selectively expressed in the brain, is
processed into shorter sequences lacking the stem sequence
that is crucial for the assembly into a functional nRNP, but still
containing the antisense box needed for targeting complemen-
tary RNA [129]. These processed snoRNAs are assembled
into nuclear RNPs involved in splicing control (sRNP). One
of those sRNP-related snoRNAs is SNORD115, which targets
the serotonin receptor 5-HT2C mRNA and inhibits its splic-
ing. This mechanism is deregulated in Prader-Willi syndrome,
a neural disease that is the most common genetic cause of
obesity [130]. Bioinformatic and functional analysis revealed
that SNORD115 controls the splicing of at least five more
genes, two of which (TAF1 and PBRM1) have been implicat-
ed in the progression from localized to metastatic castration-
resistant prostate cancer [129, 131, 132]. To date, there is not a
direct molecular link between SNORD115 and prostate can-
cer. However, this data, coupled with the function of some
oncogenic lncRNAs (e.g., ZEB2-AS1, MALAT1), strongly
suggest that splicing control can be a mechanism by which
some snoRNAs regulate cancer metastasis. SnoRNA molec-
ular functions were further broadened by the discovery that
snoRNA45 is processed to produce miRNA-like molecules in
a Dicer-dependent, Drosha-independent manner [133]. This
snoRNA-derived miRNA is processed in the cytoplasm and
triggers post-translational gene silencing on complementary
mRNAs. A subsequent study showed that at least 11 more
snoRNAs can generate functionally active miRNAs [15].
Another group of SNORNAs (U32a, U33, and U35a) is able
to shuttle to the cytoplasm and trigger cell death in response to
oxidative stress [134]. Even if the authors did not manage to
dissect the exact molecular mechanisms, this further cytoplas-
mic function of snoRNAs suggests that their roles might
extend far beyond rRNA editing.
3.1 Role of snoRNAs in cancer and metastasis
In parallel with the emergence of non-classical molecular
functions, it has become apparent that snoRNAs might play
a role in human diseases, including cancer [17, 135, 136].
Since evidence on the oncogenic roles of snoRNAs is less
advanced compared to the lncRNA field, most studies to date
have focused on the tumorigenic and proliferative functions of
those genes, overlooking their putative role in metastatic
spreading. Nonetheless, we think that this emerging evidence
strongly suggests that snoRNAs are also involved in late
stages of cancer progression. Due to their widespread require-
ment for proper protein synthesis, snoRNAs have long been
thought to work as “housekeeping” genes in different cell
types, and were therefore used as references in studies mea-
suring the expression of miRNAs in cancer patients [137].
Gee and coworkers [13] challenged this assumption, finding
that snoRNA expression in cancer samples is as variable as
miRNA expression. In addition, they demonstrated that
SNORD48 expression significantly decreases from low- to
high-grade breast cancers, and that SNORD44 up-regulation
is associated with better prognosis in both breast and non-
Fig. 2 Putative mechanisms
through which snoRNAs can
promote cancer metastasis. 1
Depicts the classical role of small
nucleolar RNAs (snoRNAs)
regulating rRNA modification,
while 2 to 4 depict the non-
classical roles through which
snoRNAs may trigger acquisition
of the metastatic phenotype in
cancer cells. Mechanisms 1 and 2
are nuclear, while 3 and 4 are
extra-nuclear. Dotted lines
indicate that the relationship to
metastasis is hypothetical
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small cell lung cancer. Even if no functional studies were
performed, those results suggest that SNORD44 and 48 might
play a tumor suppressive function in these neoplasms. In
keeping with those results, Esteller and co-workers [138]
identified three snoRNAs which are frequently silenced by
DNA methylation in a panel of cancer cell lines and clinical
samples. Notably, the same snoRNAs are not methylated and
are normally expressed in non-neoplastic tissues. Since epi-
genetic silencing of tumor suppressor genes in a common
feature of human neoplasms, these results suggest that at least
some snoRNAs may function in tumorigenesis.
The first mechanistic insight on how snoRNAs can inhibit
tumorigenesis came from a study aimed at identifying the
genetic roots of a chromosomal deletion (6q14–q22) common
to many cancer types [139]. To identify the tumor-suppressor
gene located in this region, the authors narrowed the common
region of deletion to a 2.5-Mb interval at 6q14–q15. Of the 11
genes located in this region and expressed in prostate tissues,
only SNORD50 was mutated, demonstrated transcriptional
down-regulation and inhibited colony formation in prostate
cancer cells. A few years later, the same authors demonstrated
that SNORD50 also plays a tumor-suppressive function in
breast cancer [140]. Whether SNORD50 exerts its tumor-
suppressive function through classical or non-classical mech-
anisms is still to be determined. In addition, the authors mainly
showed that this gene is able to inhibit colony formation in
cancer cells, a feature that is generally linked to the tumori-
genic potential. Future studies should dissect the molecular
pathways affected by this and other candidate tumor-
suppressive snoRNAs. It would be particularly interesting to
test the hypothesis that tumor-suppressive snoRNA play a role
not only in tumorigenesis, but also in neoplastic progression,
and particularly in metastasis.
A few snoRNAs have been also characterized as putative
oncogenes. Among them is snoRNA42, whose locus is fre-
quently amplified in lung cancer lesions. SnoRNA42 silenc-
ing leads to growth arrest and p53-dependent apoptosis in
lung cancer cells [141]. Again, the exact molecular mecha-
nism underlying this dramatic phenotypic change has not been
revealed, but the authors proposed that a snoRNA42-derived
miRNA could target p53, thereby inhibiting its pro-apoptotic
function [17]. In multiple myeloma (MM) cells, ACA11
snoRNA is a crucial component of a RNP that silences
riboproteins and snoRNAs implicated in the control of oxida-
tive stress [142]. As a consequence, ACA11 enhances MM
cell proliferation, inhibits oxidative stress response, and con-
fers chemotherapy resistance.
The evidence presented above shows that snoRNAs can
play tumor-suppressive or oncogenic functions in human neo-
plasms and that they can exert their action through several
mechanisms, some of which probably remain to be discov-
ered. Even if the link between snoRNAs and metastatic pro-
gression needs to be confirmed, we think that current
knowledge suggests that this relationship should be investi-
gated. Figure 2 shows at least three mechanisms by which
oncogenic or tumor-suppressive snoRNAs can affect
metastasis:
1. Splicing control. This is an important mechanism of ac-
tion of ZEB2-AS1 and MALAT1 lncRNAs [89, 143],
which exerts potent pro-metastatic function in several
cancer cell types. Notably, many snoRNAs (e.g.,
SNORD115 [130]) exert similar splicing control on a
wide range of genes, some of which have been implicated
with prostate cancer progression to a metastatic stage
[129, 131, 132]. It is therefore conceivable that, by con-
trolling the splicing of metastasis-driving genes those
snoRNAs could regulate the metastatic process.
2. Production of snoRNA-derived miRNAs. Classical
miRNAs are master regulators of human cancer metasta-
sis, by targeting multiple molecular pathways involved in
each step of this complex phenomenon [144]. SnoRNA-
derived miRNAs can play similar roles, thereby enhanc-
ing or inhibiting cancer progression.
3. Different sets of snoRNAs can enhance or inhibit cell
death in response to oxidative stress [134, 142]. It has
been recently shown that antioxidant pathways are acti-
vated by cancer cells to evade anoikis, a cell death pro-
gram triggered by detachment from the extracellular ma-
trix (ECM) [145]. The authors of this seminal paper
showed that detachment from the ECM strongly increases
the production of reactive oxygen species, which are toxic
for most normal and cancer cells. Only neoplastic cells
with the ability to activate antioxidant pathways can sur-
vive, thereby acquiring anchorage-independent growth
and the ability to metastasize to distant organs. Based on
this evidence, we propose that “anti-oxidative” snoRNAs
(e.g., ACA11) could enhance, while “pro-oxidative”
snoRNAs (e.g., U33) could inhibit, cancer cell
anchorage-independent growth.
To date, we found only one study directly showing that
snoRNAs are deregulated during metastatic progression. A
deep sequencing analysis investigated the whole small RNA
transcriptome in organ-confined vs . lymph-node-positive
prostate cancer samples [123]. The authors found that the
overall expression of miRNA decreased in higher tumor
stages. Strikingly, the opposite occurred for snoRNAs, most
of which were up-regulated in lymph-node-positive cases.
These results are in keeping with the evidence that a generally
increased snoRNA biogenesis is essential for breast cancer
progression [146]. The authors of the deep sequencing analy-
sis identified as many as 71 snoRNAs up-regulated (more than
twofold) in higher stage PCa, but they subsequently focused
only on the prognostic role of miRNA signatures. Thus, the
clinical relevance of the deregulated snoRNA expression
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profile needs to be fully elucidated. We think that this early
evidence provides the impetus for further analysis of snoRNA
function in metastatic PCa. For this reason, we investigated
snoRNA expression profiles in Cbio Cancer Genomic Portal
(“Prostate Adenocarcinoma MSKCC 2010” dataset) a publi-
cally available gene expression database containing data from
29 normal prostatic tissues, 131 localized, and 19 metastatic
PCa samples [147, 148].We detected 267 snoRNA genes, and
ranked them based on their differential expression in metasta-
tic vs . primary prostate cancer. Figure 3 shows the two most
differentially expressed snoRNAs, both showing a highly
significant (p <0.01, ANOVA and Tukey’s post-test) incre-
mental increase in expression through progression from nor-
mal prostate to localized and then metastatic PCa samples.
Notably, SNORD30 (which is also positively correlated with
Gleason score, p =0.01, unpaired two-tailed T test) was
among the 71 differentially expressed snoRNAs described
by Martens and co-workers [149].
Albeit preliminary and mainly based on gene expression
patterns, these results provide compelling preliminary data
suggesting that snoRNAs may be involved in metastatic pro-
gression, not unlike the better characterized miRNAs and
lncRNAs. Future studies should investigate their role in other
neoplasms, and more importantly the molecular mechanisms
underlying their pro- or anti-metastatic functions. We believe
that such analyses of this ancient class of non-coding RNAs
have the potential to reveal unexpectedmolecular insights into
the process of human cancer metastasis.
4 Conclusion: the non-coding RNA interactome and its
clinical implications
Despite being the major cause of cancer-related deaths, me-
tastasis remains a poorly understood phenomenon [24]. This
is partially due to the fact that metastatic dissemination is an
extremely complex phenomenon requiring several molecular
steps (e.g., invasion, migration, intravasation, and homing in
distant tissues). It has been suggested that the phenotypic
plasticity required for cancer cell dissemination might result
from the interaction of different molecular networks involving
protein-coding genes [20]. However, therapeutic strategies
aimed at targeting some of these pathways have produced
disappointing results in clinical trials [150–152]. We believe
this discrepancy could be at least in part explained by the idea
that protein-coding genes are not the driving factors in meta-
static progression, and that instead they lie under the
A B
C D
SNORD 26 SNORD 26
***
****
SNORD 30 SNORD 30
**
****
**
Fig. 3 Expression of two
snoRNAs in human prostate
cancer. The analysis was
performed using the MSKCC
prostate adenocarcinoma
database on cBioPortal [148]. A
total of 267 different snoRNAs
were ranked based on their ratios
of average metastatic expression
to average localized prostate
cancer expression. Here we show
the top two differentially
expressed snoRNAs, SNORD26
and SNORD30. a and c Depict
expression of SNORD 26 and
SNORD 30, respectively, in
normal individuals (29 samples)
and patients with localized (131
samples) and metastatic (19
samples) prostate cancer.
**p <0.01, ***p<0.001, and
****p <0.0001 (one-way
ANOVA and Tukey’s Test). b and
d Show the expression of
SNORD 26 and SNORD 30,
respectively, in low gleason
(117 samples) vs high gleason
(22 samples) prostate cancer.
*p< (unpaired, two-tailed
student’s
T test)
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regulation of what we have designated the non-coding RNA
interactome.
The recent discovery that the non-coding transcriptome
exceeds the protein-coding one by number and diversity, and
that many NC-RNAs are involved in cancer progression,
suggests that an uncharted molecular network might orches-
trate cancer cell dissemination (Fig. 4). It is becoming increas-
ingly clear that different classes of NC-RNAs are functionally
interconnected, and that their coordinated interactions regulate
cellular phenotypic changes in both physiological and patho-
logical conditions [153]. Based on current data, we believe the
proposed NC-RNA interactome exerts its pro-metastatic func-
tion mainly by dynamically orchestrating three fundamental
processes: epigenetic gene regulation, alternative splicing, and
antisense RNA silencing. First, epigenetic regulation is one
process in which different classes of long and short RNAs
cooperate to provide an astronomical number of functional
outputs, some of which may drive cancer metastasis. As
highlighted previously, many lncRNAs such as HOTAIR
and H19 can recruit chromatin-modifying complexes to spe-
cific loci , thus silencing anti-metastatic genes and triggering
metastatic transcriptional programs [39, 76]. In addition, there
is also mounting evidence demonstrating that small regulatory
RNAs can actively regulate chromatin dynamics by promot-
ing gene repression through the RNAi-induced transcriptional
silencing complex. Moreover, short RNAs called the piwi-
interacting RNAs (piRNAs) are emerging as key players in
epigenetic control [154]. Pioneering studies are beginning to
show that at least some piRNAs are deregulated in cancer
cells, and might play a role in metastatic progression, thereby
adding a layer of complexity to the non-coding interactome
[155]. Importantly, all these different NC-RNAs functionally
synergize to critically regulate not only the expression of
protein-coding genes but also the expression of all other
NC-RNAs critical to cancer metastasis.
In addition to epigenetic regulation, alternative splicing
represents the second molecular process in which a structur-
ally diverse set of NC-RNAs interact to generate spatial and
temporal complexity in cellular signaling pathways, underpin-
ning phenotypic plasticity. Both snoRNAs and lncRNAs have
been shown to co-localize in subnuclear compartments asso-
ciated with RNA editing [143]. Additionally, many studies
have highlighted their numerous functional contributions to
splicing control, some of which are altered during tumor
initiation and progression. Since many NC-RNAs function
as part of ribonucleoprotein complexes, it seems likely that
both snoRNAs and lncRNAs also associate with protein splic-
ing factors, and that the resulting interaction underlies the
splicing activity. We propose that the functional output of
the splicing machinery will therefore be dictated by the NC-
RNA composition (i.e., the non-coding transcriptome) of
those regulatory complexes, which can vary over time in
response to specific cues originating from the tumor microen-
vironment. Since some lncRNAs exhibit splice variant-
Non-Coding Interactome Protein-Coding Interactome          
lncRNA
snoRNA
miRNA
lncRNA
piRNA
mRNA
lncRNA
snoRNA
mRNA
mRNA
ProteinsEpigen. co-factors (2) 
Splicing Regulators (3)
METASTASIS
EPIGENETICS
ceRNA (1)
CATs (1)
miRNA-like molecules (1)
Fig. 4 Molecular networks orchestrating cancer metastasis. The non-
coding (grey boxes) and the protein-coding (white boxes) interactomes
co-operate to drive each step of the metastatic cascade (e.g., tissue
invasion, migration, intravasation, and homing in distant tissues). Differ-
ent classes of NC-RNAs can play partially overlapping functions. We
here summarize three main classes: 1 Antisense RNA inhibitors, includ-
ing miRNA-like molecules, competitive endogenous RNAs (ceRNAs)
and ceRNA-antisense transcripts (CATs); 2 epigenetic co-factors; 3
splicing regulators. Each component of the interactome can activate
(arrows) or inhibit (rectangles) other components. Epigenetic gene reg-
ulation is depicted at the border of the two interactomes, since it can
control the expression of both NC-RNAs and mRNAs. Moreover, epige-
netic effectors are composed by both proteins and lncRNAs
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dependent activity, splicing aberrations first initiated by
deregulated NC-RNA expression have the potential to propa-
gate further pro-metastatic changes by altering the activity of
other lncRNAs. Similarly, the oncogenic capacity of many
protein-coding genes is observed only in specific splice vari-
ants [156], which adds to the huge regulatory potential of the
non-coding interactome underlying alternative splicing.
The third critical juncture in our proposed RNA-based
molecular network involves the regulation of transcript stabil-
ity by antisense RNAs. By post-transcriptionally regulating
gene expression, this phenomenon has the potential to repro-
gram cellular phenotype rapidly in response to dynamic
changes in the extracellular milieu. A highly diverse set of
regulatory RNAs contribute to this process, consistent with
the existence of an interconnected regulatory network con-
trolled by NC-RNAs. Multiple RNA–RNA interactions are
involved in this complex phenomenon, all of which can
influence the functional output of this fundamental process.
First, it has been extensively demonstrated that miRNAs play
a central role by directly base pairing with target transcripts
and inducing their degradation. A number of studies have
highlighted the master regulatory role of miRNA networks
in promoting cancer metastasis [144]. While providing a solid
theoretical foundation for an RNA-based approach to cancer
progression, we believe these studies do not fully account for
all the complexity in this regulatory system. In fact, numerous
recent studies have highlighted the importance of ceRNAs in
this process, which act as miRNA buffers for protein-coding
or other non-coding transcripts [105]. This critical role of
ceRNAs implies that studies addressing differential miRNA
expression need to consider the expression of ceRNA in
interpreting the overall output of a miRNA-based pathway.
Adding to the complexity of this aspect of the non-coding
interactome, some auto-regulatory feedback loops between
ceRNA and ceRNA-antisense transcripts (CATs) [157], as
well as between short- and lncRNAs [153] have also been
reported, and there are probably many more which have yet to
be discovered. Finally, many miRNAs are directly derived
from lncRNAs or snoRNAs, once again strengthening the
hypothesis that an RNA-based molecular network controls
phenotypic plasticity in human cancers.
The current classification of NC-RNAs is mainly based on
transcript length and/or biogenesis, thereby ignoring the high
degree of functional overlap shared by some of those mole-
cules. As summarized in previous paragraphs, significant
evidence indicates that NC-RNAs with different length may
play very similar cellular functions, thereby suggesting the
need for a classification system based not on transcript size but
on molecular function. After reviewing the implications of a
non-coding interactome underlying cancer metastasis, we
now propose the first attempt to classify NC-RNA based on
functionality. As mentioned before, epigenetic regulation in-
volves a diverse spectrum of molecular interactions in which
both short and long non-coding RNAs play master regulatory
roles. To account for this functional overlap, we propose to
group together all NC-RNAs known to be involved in con-
trolling chromatin dynamics and name them “epigenetic co-
factors”. At the same time, some lncRNAs and many
snoRNAs share the property to interact with sRNP, thereby
orchestrating mRNA splicing. This second class of splicing-
related NC-RNAs could be named “non-coding splicing reg-
ulators”. Finally, it has been extensively demonstrated that
small antisense transcripts generated by miRNA, snoRNA,
and lncRNA loci can all be processed through Dicer-
dependent mechanisms, leading to complementary RNA (ei-
ther mRNA or NC-RNA silencing and degradation). We
propose to collectively name this class of NC-RNAs “anti-
sense-RNA-inhibitors”. This subclass will also include
ceRNAs and CATs. The classification system we propose
has the advantage of allowing one NC-RNA to be classified
in many groups, which reflects the extensive functional diver-
sity exhibited by the non-coding transcriptome. In addition,
this system also allows the easy addition of novel subgroups
as new molecular functions are discovered over time, making
it flexible to the numerous paradigm changes that often arise
in the search for scientific knowledge. In summary, the novel
classification system we are proposing is based on function
and not size, subclassifying individual NC-RNAs into three
groups: (1) epigenetic co-factors, (2) non-coding splicing
regulators, and (3) antisense RNA inhibitors. We believe that
as research on NC-RNA proceeds, this classification system
can become wider and more accurate.
It is worth noting that currently available NC-RNA data-
bases mainly rely on bioinformatics algorithms for the identi-
fication of non-coding sequences [158]. Functional data
confirming the non-coding nature of an RNA are limited to
few exceptions [159]. With the notable exception of miRNAs,
we currently lack a rational method for predicting NC-RNA
interactions and targets. For example, most functional studies
on lncRNA-polycomb interaction were triggered by co-
expression analyses [160] or literature-based hypotheses
[161]. A recently developed algorithm managed to predict
up to 60 % of polycomb-binding lncRNAs in mouse cells
[162], thereby paving the way to more comprehensive analy-
ses in this field. Functional confirmation of non-coding func-
tion on a broader array of candidate NC-RNAs and a system-
atic approach to NC-RNA interaction discovery will likely
enhance our understanding of the NC-interactome functions
in pathological and physiological conditions.
Finally, we believe that the hypothesis of a NC-RNA
interactome has clear implications for translational cancer
research. It has been already proposed that NC-RNAs can be
exploited as easy-to-detect biomarkers and therapeutic targets
to block cancer progression [10, 144]. Properly engineered
antisense oligonucleotides (ASOs) could be an effective tool
to target pro-metastatic NC-RNAs. Some ASOs are currently
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being tested in phase III clinical trials, notably on patients with
metastatic neoplasms [163]. Weekly administered ASOs pre-
sented an acceptable pharmacokinetic profile and were well
tolerated by oncology patients [164, 165]. Most frequent
grade 3 toxicities were fatigue and thrombocyto-lympho-
penia. ASOs off-target effects include immuno-stimulation
due to CpG-mediated Toll-like receptor activation [166].
This feature has raised some concerns on the possibility of
inducing pro-survival effects in neoplastic cells as well. On
the other hand, immunostimulatory effects could trigger an
effective anti-cancer immune response [167], thereby poten-
tiating ASO activity. It has been recently shown that targeted
nanoparticle delivery can overcome ASO off-target effects
and efficiently vehicle antisense drugs to metastatic lesions
[166, 168]. NC-RNAs are also promising biomarkers. Indeed,
one lncRNA (PCA3) is already used in the clinical setting as a
biomarker for early prostate cancer detection [32]. Both
snoRNAs and microRNAs can be detected in biological fluids
from cancer patients [169], and effectively discriminate pri-
mary vs . metastatic disease [170]. A deeper understanding of
the NC-RNA interactive network and its role in cancer metas-
tasis might therefore translate into a wide range of clinical
applications, ultimately bridging a fascinating research field
with the urgent need for more effective cancer treatments.
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